An observational study in Borderline Personality Disorder (BPD), sponsored by University Hospital, Basel, Switzerland. Withdrawn. Open to participants aged 14 Years to 18 Years. Per ClinicalTrials.gov, last updated 2022-09-13.
Sponsored by University Hospital, Basel, Switzerland · Observational
The link between epigenetic changes as an effect of psychotherapy has been investigated recently. Genes investigated in these studies were brain-derived neurotrophic factor (BDNF), NR3C1, FKBP51, MAOA and GLUT1. Change in methylation of these genes could be a biomolecular mechanism of psychotherapy induced changes. This study project aims at providing evidence for a biological mechanism of personality disorder interventions in adolescence by investigating the link between epigenetic changes as an effect of psychotherapy. It investigates the correlation between changes in the methylation of the FKBP5 gene and psychotherapy induced changes in symptoms and functioning.
336 studies on the registry are indexed under Personality Disorders; 48 are open to participants now.
Browse Personality Disorders studies →University Hospital, Basel, Switzerland is the lead sponsor of 968 studies on the registry; 191 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients in Basel/ Switzerland will be recruited from the routine clinical practice of the Outpatient Department of the Child and Adolescent Psychiatric Hospital.
Patients in Santiago/ Chile will be recruited from the Department of Psychiatry and Mental Health, East Campus,Faculty of Medicine, University of Chile.
Exclusion Criteria:
Routine psychotherapy as treatment for patients with Borderline Personality Disorder
change in methylation of the FKBP5 gene
change in methylation of the FKBP5 gene
Time frame: after 6 months from baseline
change in methylation of the FKBP5 gene
change in methylation of the FKBP5 gene
Time frame: at month 3 and at month 12 after baseline.
No study locations are listed for this record.
This study is withdrawn, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Basel, Switzerland